Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2(-) breast cancer that had progressed during or after prior endocrine therapy

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2(-) breast cancer that had progressed during or after prior endocrine therapy

Elmentve itt :
Bibliográfiai részletek
Szerzők: Musolino Antonino
Campone Mario
Neven Patrick
Denduluri Neelima
Barrios Carlos H
Cortes Javier
Blackwell Kimberly
Soliman Hatem
Kahán Zsuzsanna
Bonnefoi Herve
Squires Matthew
Zhang Yong
Deudon Stephanie
Shi Michael M
Andre Fabrice
Dokumentumtípus: Cikk
Megjelent: 2017
Sorozat:BREAST CANCER RESEARCH 19
Tárgyszavak:
Klinikai orvostan
doi:10.1186/s13058-017-0807-8

mtmt:26577127
Online Access:http://publicatio.bibl.u-szeged.hu/34299
Leíró adatok
Terjedelem/Fizikai jellemzők:14
ISSN:1465-5411

Hasonló tételek